{"schema_version":"1.0","type":"article","title":"CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease","url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.md","lang":"en","date":"2026-06-08","publish_at":"2026-06-08T10:30:00+08:00","updated_at":"2026-06-08","category":"商業分析系列","topic":"臨床與 CMC","tags":["Clinical and CMC","CAR-T","Regulatory risk","Immunology","Biotech business analysis","Drug development"],"summary":"CAR-T's move from blood cancer into autoimmune disease could redefine cell therapy, but the value depends on whether deep immune reset can justify manufacturing complexity, safety risk, and cost.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-08）。CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease。https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-08-cart-autoimmune-new-era.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}